|Bid||19.00 x 900|
|Ask||33.00 x 800|
|Day's Range||26.71 - 29.06|
|52 Week Range||24.82 - 59.03|
|Beta (5Y Monthly)||0.97|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||55.46|
Zymeworks Inc. (NYSE: ZYME), a clinical‑stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 5, 2021 (the "Meeting").
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 14.71% and -90.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2021.